Guardant Health offers the Guardant Health Portal app for healthcare professionals to track, access and download Guardant Health reports.
- Easily search, sort, and review reports
- On-call support for healthcare
professionals and patients
A simple blood draw can help clinicians
to guide therapy decisions.
A simple blood draw can help clinicians
to guide therapy decisions.
Meet Coby
A family man who was
diagnosed with advanced
cancer.
Comprehensive Genomic Profiling with a simple blood draw with an easy to interpret report.
Blood Sample
2x 10 ml tubes of blood
7 days
Comprehensive genomic
profiling results in
only 7 days
Take action
Clinically relevant
alterations
in 70+ cancer related genes.
For patients with advanced solid tumour cancers.
-
Before 1st Line Treatment
Get ahead of the challenges of tissue testing in
advanced cancer by utilizing Guardant360® to guide
1st line treatment decisions. -
At Progression
Get genomic information on over 70+ genes, including MSI
across multiple solid tumors to help inform cancer therapies and
clinical trials.
Published data
Prospective study of 323 NSCLC patients found
Guardant360® improved alteration detection
were unable to get complete
genomic results from tissue biopsy
genomic results from tissue biopsy
had targetable alterations detected
by Guardant360® and tissue testing
(n=82) versus tissue testing
alone (n=47)
by Guardant360® and tissue testing
(n=82) versus tissue testing
alone (n=47)
treated based on Guardant360® had a response or stable disease
Did you know?
Subscribe to our Newsletter
to stay up to date with information from Guardant Health.
Consistently High
Concordance with Tissue
for targetable alterations before 1st NSCLC
therapy
Consistently High
Concordance with Tissue
- Best-in-class detection
- Extensively peer reviewed and published
- Published analytical and clinical validation (refs)
- Over 150 peer reviewed publications, more than 50 of which include associated clinical outcomes
Tissue has limitations beyond your control!
- Treatment delays
Results can be unpredictable, may take a month or longer, and can be incomplete - Insufficient availability of tissue
Exhausted by diagnostic needs and PD-L1 testing - Patient burden
Repeated tissue biopsies expose patients to potential adverse events - Practice/staff burden
Significant coordination involving multiple care team members
Relying solely on tissue can lead to undergenotyping
~ 1 in 2 NSCLC patients are unable to get
guideline-recommended genes for NSCLC2-6
EGFR
ALK
ROSI
BRAF
MET
RET
ERBB2 (HER2)
NTRK
